A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
2/27/2026
BreakingPharmaPresbyopiaRegulation
US FDA Accepts sNDA for Opus’ Presbyopia Candidate, Sets PDUFA Date of Oct. 17, 2026
Commercial partners Viatris and Opus Genetics reported Feb. 25 that the US FDA had accepted the supplemental new drug application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%), targeti...
2/27/2026
BreakingCataractDry EyeOcular CancerPharmaRetinaRevenueSurgical
2025 Ophthalmic Revenue Roundup for Alcon, Apellis, Tarsus, and Immunocore
Alcon reported Feb. 24 that its full year 2025 net sales totaled $10.3 billion, a 5 percent increase over $9.8 billion in 2024. Q4-2025 sales were $2.7 billion, a 9 percent increase over $2.5 billi...
2/27/2026
BreakingOcular CancerStudy
Children’s Hospital Los Angeles Pioneers Aqueous Biopsy Test for Ocular Cancer
Researchers at Children’s Hospital Los Angeles (CHLA) have developed a liquid biopsy test of aqueous humor that they say can significantly improve the diagnosis and clinical management of tumors in...
2/23/2026
GlaucomaMeetingNewsletterPharmaSurgical
G360 Meeting Sets Fundraising Record, Shines Spotlight on Range of Stakeholders
The 2026 Glaucoma 360 meeting set a record for fundraising, with its gala taking in $715 thousand in donations and the New Horizons Forum bringing in another $462 thousand from corporate sponsorshi...
2/27/2026
BreakingDealsPharmaRetina
Outlook Grants Mediconsult Rights to Market Lytenava in Switzerland
Outlook Therapeutics announced Feb. 19 an agreement granting Mediconsult exclusive commercial distribution rights for Lytenava (bevacizumab gamma) in the Swiss market. Financial details were not di...
2/27/2026
BreakingCataractSurgical
HelpMeSee Launches Simulation-Based MSICS Training Centers in Ghana, Nigeria
Global nonprofit group HelpMeSee announced in February that it had opened new virtual training centers for manual small incision cataract surgery (MSICS) in Ghana and Nigeria. Both training centers...
2/27/2026
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Arrotex for Australia, New Zealand
Taiwan-based Formosa Pharmaceuticals announced Feb. 23 that it had agreed to license to Arrotex Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inf...
2/27/2026
AllergyBreakingClinical TrialPharmaRegulation
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
NexEos Bio reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial of NTX-1024, a topical can...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.